Cardiovascular Clinical Trials Market Size, Share, and Trends 2024 to 2033

Cardiovascular Clinical Trials Market (By Phase: Phase I, Phase II, Phase III, Phase IV; By Study Design: Interventional, Observational, Expanded Access; By Indication: Acute Coronary Syndrome, Coronary Artery Disease, Ischemic Heart Disease, Pulmonary Arterial Hypertension, Stroke, Cardiac Arrhythmias, Heart Failure, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : July 2024
  • Report Code : 4629
  • Category : Healthcare

Cardiovascular Clinical Trials Market Size and Growth

The global cardiovascular clinical trials market size was USD 5.60 billion in 2023, estimated at USD 5.94 billion in 2024 and is expected to reach around USD 10.07 billion by 2033, expanding at a CAGR of 6.04% from 2024 to 2033. The rising prevalence of cardiovascular diseases can boost the cardiovascular clinical trials market.

Cardiovascular Clinical Trials Market Size 2024 to 2033

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Cardiovascular Clinical Trials Market Key Takeaways

  • The North America cardiovascular clinical trials market reached USD 2.41 billion in 2023 and is expected to expand around USD 4.38 billion by 2033, at a CAGR of 6.15% from 2024 to 2033.
  • North America dominated the cardiovascular clinical trials market with the largest revenue share of 43% in 2023.
  • Asia Pacific is expected to grow at the highest CAGR of 6.83% during the forecast period.
  • By phase, the phase IV segment has generated more than 36% of revenue share in 2023.
  • By phase, the Phase I segment is expected to grow at a solid CAGR of 6.82% during the forecast period.
  • By study design, the interventional segment accounted for the biggest revenue share of 66% in 2023.
  • By study design, the observational segment is expected to expand at the highest CAGR of 6.42% during the forecast period.
  • By indication, the coronary artery disease segment has recorded more than 22% of revenue share in 2023.
  • By indication, the stroke segment is projected to grow at a notable CAGR of 6.52% during the forecast period.

Cardiovascular Clinical Trials Market Size and Growth 2024 to 2033

The U.S. cardiovascular clinical trials market was valued at USD 1.81 billion in 2023 and is predicted to be worth around USD 3.31 billion by 2033, at a CAGR of 6.22% from 2024 to 2033.

U.S Cardiovascular Clinical Trials Market Size 2024 to 2033

North America dominated the cardiovascular clinical trials market in 2023. The highly developed healthcare system in North America, especially in the U.S. and Canada, facilitates a large amount of clinical research. This comprises highly qualified medical personnel, cutting-edge medical technologies, and cutting-edge research centers. Due to the increasing frequency of cardiovascular illnesses in the area, there is a growing need for novel and efficient therapies. This leads to a large number of clinical trials targeted at resolving various health issues.

Numerous well-known biotechnology and pharmaceutical firms with significant R&D budgets are based in North America. These businesses carry out a significant number of clinical trials to create novel cardiovascular treatments. With one of the largest per capita healthcare spending in the world, North America is able to fund a significant amount of research and development, including cardiovascular disease clinical trials. Clinical trials in the region are more efficient and successful when cutting-edge technology like telemedicine, big data analytics, artificial intelligence, and electronic health records are integrated.

Cardiovascular Clinical Trials Market Share, By Region, 2023 (%)

Asia Pacific is expected to grow at the highest CAGR in the cardiovascular clinical trials market during the forecast period. The pharmaceutical and biotechnology businesses find Asia Pacific intriguing since clinical trial costs are cheaper there than in North America and Europe. This entails reduced labor, patient acquisition, and operating costs.

The vast and genetically heterogeneous population in the area offers a wide range of trial candidates, which is advantageous for the validity and applicability of clinical trial findings. Clinical trial conduct is getting easier as a result of the streamlining and harmonization of regulatory frameworks with international norms in many Asia Pacific nations. This includes more open regulatory rules and expedited approval processes.

Cardiovascular Clinical Trials Market Overview

The cardiovascular clinical trials market refers to the subsector of the clinical trials industry for cardiovascular diseases. These investigations are conducted to assess the efficacy, safety, and possible advantages of novel therapies, medications, equipment, or interventions intended to prevent, identify, or manage cardiovascular illnesses. Heart failure, hypertension, arrhythmias, coronary artery disease, and other problems affecting the heart and blood arteries are among these diseases.

The development and validation of novel therapies and interventions that can enhance the identification, treatment, and prognosis of cardiovascular illnesses depend heavily on cardiovascular clinical trials. The cardiovascular clinical trials market is fragmented with multiple small-scale and large-scale players, such as SGS SA, Worldwide Clinical Trials, Eli Lilly and Company, Veeda Clinical Research, PPD Inc, Syneos Health, Vial, IQVIA Inc, Caidya, ICON plc, Medpace, Inc.

Cardiovascular Clinical Trials Market Growth Factors

  • Rising healthcare expenditure can boost the cardiovascular clinical trials market.
  • The rising aging population can grow the cardiovascular clinical trials market.

Cardiovascular Clinical Trials Market Scope

Report Coverage Details
Market Size by 2033 USD 10.07 Billion
Market Size in 2023 USD 5.60 Billion
Market Size in 2024 USD 5.94 Billion
Market Growth Rate from 2024 to 2033 CAGR of 6.04%
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Phase, By Study Design, By Indication and Region
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Cardiovascular Clinical Trials Market Dynamics

Driver

Rising demand for drugs for cardiovascular diseases

The rising demand for drugs for cardiovascular diseases can boost the cardiovascular clinical trials market. Effective therapies are becoming more and more necessary as cardiovascular disorders become more common. This results in an increase in clinical studies testing novel medications & treatments. As the world's population ages, cardiovascular illnesses become more common, increasing the need for novel therapies and the number of clinical trials needed to produce them.

Restraint

High cost of research

The high cost of research may slow down the cardiovascular clinical trials market. The high cost of research might restrict the amount of money available. The clinical trials may be postponed or discontinued as a result of smaller businesses or academic institutions' inability to get adequate financing.

Opportunity

Integration of technologies

The integration of technology can be the opportunity to boost the cardiovascular clinical trials market. The process of better data collection and analysis, improved patient recruitment and retention, streamlined trial procedures, personalized medicine enabled, remote monitoring made easier, big data and AI leveraged, data security guaranteed, and a variety of VR and AR applications, technology integration can dramatically increase the market for cardiovascular clinical trials.

Phase Insights

The phase IV segment dominated the cardiovascular clinical trials market in 2023. Due to a number of significant factors that emphasize the significance and distinctive qualities of this stage of clinical research, the phase IV segment controlled the cardiovascular clinical trials market by phase in 2023. Phase IV studies, often referred to as post-marketing surveillance trials, are carried out following the public approval of a therapy. The monitoring of the long-term safety and effectiveness of cardiovascular therapies in a larger patient group requires phase IV studies. Any unusual or long-term negative effects that might not have been noticeable in previous periods are identified with the assistance of this continued observation. These studies gather empirical data about the performance of therapies outside the controlled setting of previous clinical trials, offering important new perspectives on the efficacy of these interventions in everyday clinical practice.

The phase I segment is expected to grow at the highest CAGR in the cardiovascular clinical trials market during the forecast period. Increased funding for early-stage research, the rise in cardiovascular disease prevalence, technological advancements, regulatory support, the emergence of new therapeutic areas, collaboration and partnerships, an emphasis on safety and risk management, and improved patient recruitment and engagement are the main factors driving the expected high growth rate of the phase I segment in the market during the forecast period. All of these elements work together to highlight how important phase I trials are to the creation of novel cardiovascular therapies and the general growth of the cardiovascular clinical trials market.

Study Design Insights

The interventional segment dominated the cardiovascular clinical trials market in 2023. The intended effect of interventional trials is to evaluate the safety and effectiveness of novel medications, medical devices (like pacemakers or stents), treatments (like coronary artery bypass grafting), or combinations of these. These studies frequently assess the efficacy of experimental medications in comparison to placebos or accepted treatments, offering vital information for clinical decision-making. For novel medicines to be approved for clinical use by regulatory agencies, strong evidence from interventional studies is necessary. Before advanced treatments are widely used, these studies are crucial to proving their safety, effectiveness, and advantages. The interventional category trials follow strict requirements established by regulatory bodies such as the European Medicines Agency (EMA) in Europe and the Food and Drug Administration (FDA) in the United States.

The observational segment is expected to grow at the highest CAGR in the cardiovascular clinical trials market during the forecast period. Because they don't entail the administration of novel drugs or intensive laboratory testing, observational studies usually need less budget than interventional trials. This increases their viability for a wider group of scientists and organizations. Regulations, payers, and healthcare providers are beginning to place a greater emphasis on observational studies because they offer practical information on how therapies function in everyday clinical practice. By shedding light on therapy efficacy and safety across a larger patient group, these data can supplement randomized controlled trials (RCTs). When it is unethical to withhold therapy from a control group, as might be the case with severe cardiovascular problems, observational studies are frequently used. These kinds of investigations enable researchers to get important information without sacrificing patient care.

Indication Insights

The coronary artery disease segment dominated the cardiovascular clinical trials market in 2023. Coronary artery disease is a common and frequently deadly cardiovascular illness that affects people all around the world. Because of the condition's high prevalence and high fatality rate, clinical trials and research are essential. Despite advances in treatment, there is a great need for safer and more effective CAD medications. This drives a large lot of clinical research to create better therapy solutions. To evaluate the safety and effectiveness of novel drugs, technologies, and treatments for coronary artery disease (CAD), extensive clinical trials are necessary. Novel anti-platelet medications, cholesterol-lowering drugs, and cutting-edge stent technology are a few examples of them.

The stroke segment is expected to grow at the highest CAGR in the cardiovascular clinical trials market during the forecast period. The need for novel and efficient therapies for stroke, which continues to be a major cause of mortality and disability globally, is fueling the expansion of clinical studies in this field. There is a greater need for research into stroke prevention, acute care, and rehabilitation as the aging population worldwide is more likely to experience a stroke. Growth in this market is being driven by recent developments in stroke therapy, such as thrombectomy devices, clot-busting medications, and neuroprotective medicines, which require extensive clinical studies to assess their safety and efficacy. Early intervention is becoming more and more important in avoiding strokes and improving outcomes. More clinical trials with the goal of determining efficient methods for early identification, risk mitigation, and acute therapy have resulted from this.

Cardiovascular Clinical Trials Market Companies

  • IQVIA Inc
  • ICON plc
  • SGS SA
  • Eli Lilly and Company
  • PPD Inc
  • Syneos Health
  • Caidya
  • Worldwide Clinical Trials
  • Vial
  • Veeda Clinical Research
  • Medpace, Inc.

Recent Developments

  • In April 2024, Advances in medical therapy may lead to a significant reduction in the need for implanted cardioverter defibrillators (ICD) for patients with heart failure, according to a $27 million study being conducted by cardiac experts at the University of Rochester Medical Center (URMC).
  • In March 2024, A clinical study for bras that might help identify cardiac abnormalities and other issues that can cause heart disease is scheduled to begin at a small company in Cambridge.
  • In February 2024, CU Safety Gene therapy trials for heart disorders are about to begin. Three decades of research on dilated cardiomyopathy have produced ground-breaking findings. It began as a record of people with cardiac conditions in the early 1990s. The current generation of medicines for dilated cardiomyopathy is being informed by data gathered from over 2,000 families.
  • In September 2023, the Ohio State University Wexner Medical Center randomized the world's first patient in a clinical study testing a gadget intended to reduce heart failure symptoms. The first patient is a 54-year-old Bellefontaine, Ohio, man whose acute dyspnea was brought on by heart failure.

Segment Covered in the Report

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Study Design

  • Interventional
  • Observational
  • Expanded Access

By Indication

  • Acute Coronary Syndrome
  • Coronary Artery Disease
  • Ischemic Heart Disease
  • Pulmonary Arterial Hypertension
  • Stroke
  • Cardiac Arrhythmias
  • Heart Failure
  • Others

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

The global cardiovascular clinical trials market size is expected to increase USD 10.07 billion by 2033 from USD 5.60 billion in 2023.

The global cardiovascular clinical trials market will register growth rate of 6.04% between 2024 and 2033.

The major players operating in the cardiovascular clinical trials market are IQVIA Inc, ICON plc, SGS SA, Eli Lilly and Company, PPD Inc, Syneos Health, Caidya, Worldwide Clinical Trials, Vial, Veeda Clinical Research, Medpace, Inc., and Others.

The driving factors of the cardiovascular clinical trials market are the

North America region will lead the global cardiovascular clinical trials market during the forecast period 2024 to 2033.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cardiovascular Clinical Trials Market 

5.1. COVID-19 Landscape: Cardiovascular Clinical Trials Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cardiovascular Clinical Trials Market, By Phase

8.1. Cardiovascular Clinical Trials Market Revenue and Volume, by Phase, 2024-2033

8.1.1 Phase I

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Phase II

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Phase III

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Phase IV

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Cardiovascular Clinical Trials Market, By Study Design

9.1. Cardiovascular Clinical Trials Market Revenue and Volume, by Study Design, 2024-2033

9.1.1. Interventional

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Observational

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Expanded Access

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Cardiovascular Clinical Trials Market, By Indication 

10.1. Cardiovascular Clinical Trials Market Revenue and Volume, by Indication, 2024-2033

10.1.1. Acute Coronary Syndrome

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Coronary Artery Disease

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Ischemic Heart Disease

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. Pulmonary Arterial Hypertension

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

10.1.5. Stroke

10.1.5.1. Market Revenue and Volume Forecast (2021-2033)

10.1.6. Cardiac Arrhythmias

10.1.6.1. Market Revenue and Volume Forecast (2021-2033)

10.1.7. Heart Failure

10.1.7.1. Market Revenue and Volume Forecast (2021-2033)

10.1.8. Others

10.1.8.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Cardiovascular Clinical Trials Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Phase (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by Study Design (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by Indication (2021-2033)

Chapter 12. Company Profiles

12.1. IQVIA Inc

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. ICON plc

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. SGS SA

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Eli Lilly and Company

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. PPD Inc

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Syneos Health

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Caidya

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Worldwide Clinical Trials

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Vial

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Veeda Clinical Research

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client